Pfizer's heart disease drug remains 'mainstay treatment' despite new entries, Oppenheimer says

Brokerage Oppenheimer says that despite BridgeBio's BBIO.O heart disease drug seeing rapid early uptake, there remains preference for competitors like Alnylam's ALNY.O Amvuttra and Pfizer's PFE.N Vyndamax

Vyndamax remains the mainstay treatment, according to brokerage's survey

Entry of Amvuttra may slow growth of BridgeBio's Attruby, as doctors' interest in Alnylam's drug is high

Brokerage adds that despite the apparent preference diagnosis rates and drug access should be improved with competition, although analysts estimates look very low for near-term Attruby sales

Analysts expect 2025 sales of $162.43 million for Attruby, according to 3 analysts as per LSEG data

The drugs are approved for ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart, potentially causing the organ to fail

Brokerage also sees substantial concern over the durability of sales, particularly with anticipated generic entry in 2029

Adds that Alnylam's decision to maintain premium pricing may sway insurers to other drugs, while Attruby's lower price appears to lack strategic value for BBIO

Up to last close, PFE down 3.7%, ALNY up 19.4% and BBIO down 33.9% YTD